Palbociclib (Ibrance) Manufacturer: Pfizer Inc., New York, New York Date of Approval: February 3, 2015 Indication: Palbociclib is indicated, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
展开▼
